FMG Biomed, Inc.

FMG Biomed pioneers next-generation regenerative biomaterials for advanced wound care. Our core breakthrough is the patented nPCM (non-reconstituted porous collagen matrix) technology, developed by CEO Distinguished Prof. Lynn L.H. Huang. Unlike traditional scaffolds that collapse in wound fluids, our chemical-free nPCM retains a stable, high-purity, and biocompatible 3D structure. Our flagship RegDerm™, derived from nPCM, is a regenerative dermal prosthesis for trauma and ulcers. It precisely guides the rapid regeneration of microvessels and tissues, sparing patients with diabetic foot ulcers and extensive trauma from the secondary trauma of skin grafts and flaps. Disrupting regenerative medicine through breakthrough science, we are committed to becoming the ultimate global solution for tissue engineering and advanced wound care.